

Group 2: Claims 1-8, 11, 22-25, and 28, drawn to methods of administering compounds with identical or similar effects as SEQ ID NO:2 or 4, to the extent that the claims encompass administration of products of undefined structure;

Group 3: Claims 14-16, 31-33, 40, and 52-60 drawn to compounds of undefined structure with identical or similar effects as SEQ ID NO:2 or 4;

Group 4: Claims 53-65, drawn to compounds that are related by sequence identity to SEQ ID NO:2;

Group 5: Claims 17 and 20-21, drawn to methods comprising administering a GIP antagonist of undefined structure;

Group 6: Claims 18 and 46-47, drawn to methods comprising administering an antibody;

Group 7: Claims 19 and 48-49, drawn to methods comprising administering a GIP receptor antagonist;

Group 8: Claims 34-35, drawn to methods of administering compounds of undefined structure;

Group 9: Claims 36 and 39, drawn to a method comprising administering to a subject a pharmaceutical composition comprising a GIP antagonist of undefined structure;

Group 10: Claims 37 and 50, drawn to methods of administering an antibody to GIP;

Group 11: Claims 38 and 51, drawn to methods of administering an antagonist of a GIP receptor of undefined structure;

Group 12: Claim 41, drawn to a method comprising providing a compound for a manufacture of a pharmaceutical composition; and

Group 13: Claims 42-45, drawn to methods of determining an abnormal GIP level.

Applicants hereby elect the invention of Group I, claims 1-13 and 22-30, without traverse.

Conclusion

It is believed that this paper is fully responsive to the outstanding requirement for claim election. Accordingly, consideration of these remarks is respectfully requested.

Dated: April 19, 2007

Respectfully submitted,

By 

Paul M. Zagar

Registration No.: 52,392

DARBY & DARBY P.C.

P.O. Box 5257

New York, New York 10150-5257

(212) 527-7700

(212) 527-7701 (Fax)

Attorneys/Agents For Applicant